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Abstract
Background/Purpose: The purpose of this literature appraisal is to determine the effectiveness
of tranexamic acid (TXA) and its ability to stabilize postpartum bleeding. TXA is an
antifibrinolytic pharmacologic drug found to reduce blood loss associated with trauma and
patients undergoing major surgeries. When administered in combination with other uterotonics,
the World Health Organization predicts the prophylactic use of TXA could globally improve the
morbidity and mortality rates associated with postpartum hemorrhaging.
Theoretical Framework: Kurt Lewin’s change theory was used in the development of this
literature review. The Lewin change theory emphasizes the importance of change and
development within a medical institution. Lewin’s theory is categorized into three stages
consisting of the unfreezing, change, and refreezing models.
Methods: Twenty research articles that pertained to postpartum hemorrhaging and/or the effects
of TXA on postpartum bleeding were assessed. The Johns Hopkins research evidence appraisal
tool was used to evaluate all articles included in this literature appraisal.
Results/Findings: The need for TXA among various maternal groups was assessed. High risk
patients were found to be in greater need for TXA during postpartum care. TXA has also been
found to reduce the need for uterotonics, improve hemoglobin and hematocrit levels, and
decrease rates of postpartum hemorrhaging. Potential adverse effects and costs associated with
TXA use were also explored.
Implications for Research and Practice: The prophylactic use of TXA is significant to
midwifery and caring for women. Midwives may administer TXA to reduce the patient’s risk of
maternal death and injury related to postpartum bleeding. The use of TXA is particularly
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important for healthy postpartum transitions among at-risk patients and patients in developing
nations. Keywords: Postpartum hemorrhaging, Postpartum hemorrhage, Tranexamic acid (TXA),
Kurt Lewin Theory, vaginal birth, cesarean birth
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Chapter 1: Introduction
There is universal consternation surrounding labor and childbirth, including
hemorrhaging during the postpartum period. The threat of experiencing a postpartum
hemorrhage can be debilitating for women. Excessive bleeding during the postpartum period
increases rates of morbidity and mortality among maternal patients. According to the American
College of Nurse Midwives (ACNM; 2017), women who have suffered from postpartum
hemorrhaging are at increased risk of organ shock and long term disability.
Laboring women across the globe are at risk for postpartum bleeding. The ACNM (2017)
reports that roughly 125,000 women in the United States experience a postpartum hemorrhage
every year. In addition, an estimated 130,000 maternal deaths are associated with postpartum
hemorrhaging throughout the globe (ACNM, 2017). In fact, hemorrhaging is the leading cause of
maternal morbidity in the United States (American College of Obstetrics and Gynecologist
[ACOG], 2017). Postpartum hemorrhage has also been identified as a leading cause of maternal
death in developing countries (World Health Organization [WHO], 2017). The WHO (2017)
reported over a quarter of global maternal deaths are associated with bleeding, which occurs in
the third and fourth stages of labor. Postpartum bleeding may occur up to 6 weeks after the
delivery; however, the majority of bleeds occur during the first 24 hours of delivery. The WHO
(2017) defines postpartum bleeding as blood loss exceeding 500 ml. Bleeding that surpasses
1,000 ml within 24 hours is classified as severe postpartum hemorrhaging (WHO, 2017). While
uterine atrophy remains the leading cause for postpartum bleeds, hemorrhaging can also be
associated with vaginal and cervical lacerations, retained placenta, and uterine rupture; in these
cases, women with little or no preexisting risk may experience a hemorrhage (WHO, 2017).
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However, pre-existing maternal comorbidities will increase a patient's risk of excess bleeding
(WHO, 2017). For example, patients suffering from anemia or coagulation disorders may be at
an increased risk for bleeding or may display more severe symptoms from postpartum bleeds
(WHO, 2017).
Statement of Purpose
The purpose of this literature review is to assess postpartum outcomes related to
tranexamic acid (TXA) use in the third and fourth stages of labor. TXA is an antifibrinolytic
agent used to stabilize bleeding. Postpartum hemorrhaging is the leading cause of death during
childbirth. Numerous studies were evaluated to determine the benefits and effects of TXA during
the third and fourth stages of labor (WHO, 2017). This paper will examine the effects of TXA
treatment on maternal hemorrhaging, cost efficiency in midwifery, and maternal delivery modes.
Evidence Demonstrating Need
The management of postpartum hemorrhaging is vital to maternal well-being. To improve
postpartum outcomes, our health care system requires adjustments that incorporate TXA into
routine obstetric care. During the postpartum transition, minimal blood loss is expected; blood
loss up to 500 ml is a natural occurrence during the third stage of labor (WHO, 2017). However,
blood loss surpassing 500 ml is considered a hemorrhage (WHO, 2017). The majority of
postpartum bleeds occur during the third and fourth stages of labor during which a midwife is
responsible for treating and stabilizing the patient's bleeding (WHO, 2017).
In current obstetric care, patients are treated with expectant or active management;
midwives determine patient care based on their preferences and hospital policies (WHO, 2017).
Midwives practicing expectant treatment allow the placenta to separate from the uterine wall
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without manual assistance. The placenta is spontaneously delivered with nipple stimulation,
maternal pushing, and gravity. During expectant treatment, the midwife does not clamp the
umbilical cord until it ceases to pulsate and post-delivery uterotonics are not routinely provided.
During expectant management, the body undergoes the postpartum transition with minimal
assistance from the midwife; however, patients are also at greater risk for significant postpartum
bleeding. Therefore, the WHO (2017) has recommended providers practice active rather than
expectant management.
Active management reduces postpartum hemorrhaging incidences (WHO, 2017). With
active management, the midwife stabilizes the patient with various interventions, including
routine treatment of postpartum patients with post-delivery uterotonics (WHO, 2017). Midwives
currently use intravenous (IV) oxytocin, intramuscular (IM) oxytocin, misoprostol, syntometrine,
and IM ergometrine. Of these treatment options, the WHO (2017) recommends routine use of IV
or IM oxytocin. Uterotonics can be appropriately administered during multiple time points
including the crowning of the fetus, delivery of the anterior shoulder, delivery of the fetus, and
before or after placental delivery (WHO, 2017). Delayed cord clamping is also recommended
during active management. The midwife will begin cord traction when signs of placental
separation are observed (WHO, 2017). Cord traction may also be initiated before spontaneous
placental separation. In addition to cord traction, midwives may also implement uterine massage.
Midwives also play an active role in assessing uterine tone and bleeding every 15 min during the
fourth stage of labor (WHO, 2017). ACNM (2017) has suggested active management will:
●

Reduce the need for transfusion of blood products

●

Reduce rates of postpartum hemorrhaging
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●

Minimize the use of additional uterotonics within 24 hr of the postpartum recovery
period (as cited in WHO, 2017)
The WHO (2017) supports TXA use in postpartum management. In their millennium

development goals report, the WHO (2017) addressed the need for obstetric service refinement.
According to Callaghan et al., (2010) postpartum hemorrhaging increased 26% from 1994 to
2006. However, the WHO has determined prompt improvements to the third stage of labor will
decrease postpartum bleeding occurrences among mothers (WHO, 2017). Therefore, the WHO
(2017) recommended adding TXA to active care in the third and fourth stages of labor. TXA can
decrease postpartum hemorrhaging incidences, particularly in low-income communities, and
prevent mortality and morbidity rates associated with childbirth. The ACNM (2017) also
supported the use of TXA post vaginal and cesarean deliveries. Accordingly, the midwifery
hallmark supports TXA use to promote health, prevent disease, and educate women. Midwifery
standards to “incorporate evidence-based care into clinical settings” also justifies TXA use
(ACNM, 2020, p. 1). TXA was originally used to manage blood loss during major surgeries
(American College of Obstetricians and Gynecologist [ACOG, 2017]). In recent years, the
antifibrinolytic agent has shown effectiveness during the management of postpartum
hemorrhaging. Uterotonics are currently used in routine postpartum care; however, evidence has
supported the use of TXA in combination with uterotonics, (ACOG, 2017) because TXA may be
safely combined with routine uterotonics. Therefore, the WHO (2017) has supported the use of
TXA to minimize and prevent excessive bleeding post-delivery during the transition phase.
Midwives are encouraged to administer TXA within 3 hr of delivery (Mielke & Obermeyer,
2020). To adhere to evidence-based practice, midwives are responsible for incorporating TXA
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into postpartum care. Continuous change and patient care updating are encouraged in midwifery.
ACOG (2017) found updates in obstetrical practices have improved maternal outcomes by 10%
from 1989 to 2009. The WHO (2017) has suggested that including TXA in midwifery practice
will also increase rates of positive maternal outcomes. However, challenges may slow the
process of TXA use in obstetric care. Although ACOG (2017) has recognized the benefits of
TXA, the drug has been placed in Stage 2 of the algorithm for postpartum hemorrhaging. IV
hydration, oxytocin, hemabate, and methergine are considered first line drugs. Therefore, the
algorithm supports TXA use when first line uterotonics have failed. Nevertheless, Simonazzi et
al. (2015) found TXA was most effective when given prior to maternal hemorrhage. These
findings suggested TXA should be considered as a routine drug for blood loss management in
obstetrical care.
Significance to Nurse Midwifery
Midwives have practiced for millennia. Midwifery has been used as early as biblical
times. The Bible recognizes midwives as vital components of the birthing process, stating “God
was good to the midwives, and the people multiplied and became more numerous” (King James
Bible, 1769/2017, Exodus 1:20). The Hebrew word for midwife translates to “childbirth-assisting
woman.” The first biblical reference to midwifery is in the account of Rachel's birth to Benjamin.
The Bible depicted Rachel's childbirth experience as long and strenuous. Yet, the midwife was
able to calm Rachel and help her bond with her son and name him (King James Bible,
1769/2017, Genesis 35:17).
Since the start of midwifery, midwives have been responsible for assisting women with
birth and newborn bonding. The Frontier School of Midwifery was established in 1925, initiating
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nurse-midwifery as a recognized profession in the United States (CITE). Today, midwives are
qualified to provide care and treatment to women from adolescence to menopause. Certified
nurse-midwives have mastered two medical competencies: nursing and a master or doctorate
degree specializing in nurse-midwifery. All certified nurse-midwives must complete their
midwifery education from a facility approved by the Accreditation Commission for Midwifery
Education. Upon achieving a graduate degree in midwifery, graduates are required to pass the
American Midwifery Certification Board exam (ACNM, 2020).
The majority of issues in women’s services could be ameliorated with the assistance of a
midwife. Improvements are made to maternal and newborn health when midwifery philosophy is
applied to patient care. The midwife empowers women to take control of their bodies while
promoting patient education and natural paths to labor and childbirth. The WHO (2017) has
stressed the significance of midwives, defined as skilled practitioners who aim to provide
optimal care to women, families, and infants. The use of midwives will improve maternal and
newborn outcomes while globally ensuring justice for women (WHO, 2017). Midwifery care is
also cost efficient and therefore feasible for low-income communities to reinforce (WHO, 2017).
The WHO (2017) has found multiple benefits associated with midwifery services with no
adverse effects linked to midwifery care.
Certified nurse-midwives play an instrumental role in ensuring the well-being of both
women and newborns. Therefore, the ACNM (2017) encourages the global use of midwives for
practicing midwives to adhere to the pearls of midwifery; that is, midwives should provide
patient care according to evidence-based medical standards, collaboration among medical staff,
and midwifery professional judgement. While the ACNM values patience and minimal
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intervention, the midwifery pearls also acknowledge the need for prompt, evidence-based
intervention and attendance to the patient’s physical, mental, and spiritual needs.
Proper implementation of midwifery pearls promotes optimal maternal outcomes and
limits adverse effects. Midwives serve as experts in primary gynecological, pregnancy, and
postpartum care (ACNM, 2020). Therefore, midwives have a significant influence on the
prevalence and subsequent management of postpartum hemorrhaging. During the postpartum
stage, midwives are responsible for performing early assessments for postpartum bleeding
(Mamakou, 2020). In the presence of a postpartum hemorrhage, midwives initiate early
intervention to stabilize blood loss, thereby preventing further obstetrical maladies (Mamakou,
2020). According to the ACNM (2020), there is approximately a 12% increase in positive
outcomes among women and newborns who have received midwifery care, meaning the
implementation of midwives can reduce mortality and morbidity rates associated with
postpartum hemorrhaging.
Theoretical Framework
All women desire a safe delivery. Yet, hemorrhaging remains one of the leading causes of
death among postpartum mothers (Alam & Choi, 2015). To protect mothers, midwives must
become educated on the use of TXA. However, adapting to evidence-based practice can be a
difficult task. Therefore, the present investigation considered Kurt Lewin's change theory.
Change theory illustrated strategies on proper implementation of current practice into health care
settings, including midwifery (Shirey, 2013). The purpose of change theory was to aid
institutions in the process of transitioning from present practice to the desired practice in a threestep process.
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The first step in Lewin’s change process is unfreezing (Lewin’s et. al, 1951). During
unfreezing, the health care institution prepares medical staff for change that will take place in the
medical practice. The unfreezing stage is necessary to eliminate potential resistance to change
among staff and identify the changing focus. During the unfreezing process, nurses, managers,
and providers are presented with issues associated with the current practice and the need to make
alterations that would improve patient outcomes. This stage encourages institutions to include
staff members in the planning process for implementing modifications to patient care (Lewin’s
et. al., 1951). Shirey (2013), also recommended round table meetings. During these meetings,
staff nurses discuss their potential concerns surrounding TXA implementation. Providers are also
presented with the opportunity to question the change implementation process and offer their
feedback to the organization. The incorporation of medical staff strengthens the team’s
understanding of the need for change and decreases staff member’s resistance to change.
Upon completing the unfreezing stage, midwives in the institution have acknowledged
the need for alteration and may therefore initiate reform. Thus, the second step of Lewin’s et. al.,
(1951) process is the change stage for implementing the updated medical practice. During this
stage, collaboration between the organization and staff members is encouraged to determine how
and when to install change into the medical setting. During the change period, providers abandon
their dedication to former practice. At this time, the organization may begin to train staff
members on safe practices and medical policies. Coaching and mentoring programs may also be
initiated to improve confidence among medical staff during the change period.
The third and final step of Lewin’s et. al., (1951) theory is refreezing. The purpose of the
refreezing stage is to commit to the updates made in inpatient care. During this phase, change is
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stabilized and reinforced to prevent midwives from reverting to former habits. To promote the
continuation of refreezing, the institution must practice continuation of education and staff
training. The refreezing stage also requires constructive criticism from management. Feedback
and reward from management encourage staff members to consistently practice according to the
organizational changes made.
Kurt Lewin's (1951) change theory serves as an appropriate framework for TXAs
prophylactic effects on mothers during the transition period. The theory addresses three strategies
affiliated with implementing change in an institutional setting (Hussain et al., 2018). The three
strategies include, in the following order unfreezing, changing, and finally refreezing. The
purpose of this sequence is for midwives to acknowledge recent evidence supporting TXA use
and update their practice according to evidence-based care (Shirey, 2013). In this instance, the
midwife would implement routine prophylactic use of TXA across multiple work settings
including hospital, clinic, and home births. TXA would be administered during the third stage of
labor, preferably 2 hours post-birth (Shirey, 2013).
Summary
The use of TXA among midwives promotes optimal patient outcomes. Applying Lewin's
theory to TXA administration may promote education on when and how to implement TXA use
for midwives internationally. TXA is a cost-efficient drug available to many countries across
various settings (Hussain et al., 2018). Therefore, the antifibrinolytic agent can be readily
available to women who have risk factors for hemorrhaging and are in low-income settings. The
availability of TXA is significant as it supports the midwifery hallmark to “utilize an
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understanding of social determinants of health to provide high-quality care to all persons
including those from underserved communities” (ACNM, 2020, p. 1).
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Chapter 2: Methods
This chapter explores the strategies set in place to identify and review literature on the
effects of TXA when given within 3 hours of birth. This chapter also describes search strategies
and criteria for inclusion and exclusion. In total, 20 articles met criteria for inclusion. Finally,
this chapter considers evaluation criteria for identifying quality and level of evidence across
articles.
Search Strategies
Research databases were used to search for applicable studies, including EBSCO, Google
Scholar, PubMed MEDLINE, and CINAHL. Key search terms included TXA, postpartum
hemorrhaging, and vaginal and cesarean deliveries. Searches were conducted for articles
published between 2010 and 2020. Due to constant changes in medical standards, articles
published within the last 10 years were retrieved to ensure the most up to date data. A total of
300 abstracts were retrieved and reviewed. After retrieving articles, their reference lists were
reviewed to identify additional scholarly studies. After the elimination of duplicate articles and
applying inclusion and exclusion criteria, a total of 20 articles were appropriate for the purpose
of this literature appraisal.
Criteria for Inclusion and Exclusion
The studies included in this literature appraisal needed to be original research that
addressed the effectiveness of TXA during management of postpartum bleeding. Selected articles
evaluated the impact of postpartum TXA use related to route and time of administration.
Included articles also explored birthing risk factors and potential interactions or adverse effects
associated with maternal TXA use.
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The exclusion criteria included systemic reviews, study protocols, and articles published
prior to 2010. Studies that did not offer a full text in English were also excluded from this
literature appraisal. Furthermore, treatment for bleeds during pregnancy, or TXA use for neonatal
trauma patients were excluded from the matrix.
Summary of Selected Articles
After careful review, 20 articles comprising various studies were included in this review.
The included articles consisted of one observation study, one prospective cohort study, one quasiexperimental study, and 17 randomized controlled trials. Studies were included from various
countries within North America, Europe, Africa, Asia, and the Middle East.
Evaluation Criteria
The quality and strength of articles were appraised using the John Hopkins research
appraisal tool. This tool determines strength by measuring articles on a scale of 1 to 5. Level 1
articles are randomized control trials and are the highest level of scientific evidence strength.
Level 2 articles are quasi-experimental studies. Level 3 studies include qualitative and
nonexperimental studies. Level 4 studies include consensus panels and clinical practice
guidelines. Finally, Level 5 articles include clinical reviews, case reports, and opinions of
national experts. This literature review included 17 randomized, one quasi-experimental, and two
observational studies, with randomized control trials as the majority. According to the research
appraisal tool, randomized experiments have the highest strength and are therefore graded as
Level 1. One quasi-experimental article was included in this appraisal. Quasi-experiments are
second in strength and are therefore graded as a Level 2. Qualitative and nonexperimental studies
are graded as Level 3.
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After establishing the article’s strength, the John Hopkins research appraisal tool
determines the quality of the experiment. Article quality was categorized into three levels: (a)
strong, (b) good, and (c) poor. The studies in this literature review were classified as either strong
or good. Seven of the included articles were strong quality and 13 articles were classified as
good quality. Dearholt and Dang (2018) defined strong quality studies as research with a large
enough sample size to produce generalizable results. Strong sources produce scientific results
that are used to implement recommendations. Good articles also include generalizable and
scientific data, however, data is presented in a lesser form. Lastly, poor articles are those with
low quality data. These articles lack sufficient scientific data, sample size, and author
recommendations.
Summary
For this literature appraisal, articles were retrieved from the Bethel Library, EBSCO,
Google Scholar, PubMed MEDLINE, and CINAHL. Appropriate articles for this literature
review were determined using the inclusion and exclusion criteria. In total, 20 articles were
included in this literature review. Articles were then assessed for strength and quality using the
John Hopkins appraisal tool.
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Chapter 3: Literature Review and Analysis
Synthesis of Matrix
The matrix was used to display the scholarly articles presented in this literature appraisal
and divided into the following sections: purpose, sample, design, measurement, results/
conclusions, recommendations, level, and quality (See Appendix A). The Johns Hopkins research
evidence appraisal tool was used to establish article strength and quality. Matrix citations were
organized in alphabetical order.
Synthesis of the Major Findings
The following literature review demonstrates evidence on the ability for TXA to improve
postpartum hemorrhaging during the third and fourth stages of labor. This review will highlight
the route of TXA administration, variations in time of administration, the impact of TXA on
high-risk patients, potential adverse effects of TXA, and the cost-effectiveness of the drug.
Administration
The most effective route and timing of TXA administration in the obstetrical setting has
been under review. The WHO (2017) has suggested giving 1 g TXA via IV over 10 min within 3
hr postpartum. This review included 15 articles that examined the administration of TXA (Bose
& Beegum, 2017; Chandak et al., 2017; Diop et al., 2020; Durand-Zaleski et al., 2020, Gillissen
et al., 2017; Gungorduk et al., 2013; Lakshmi, 2016; Ramesh et al., 2015; Roy et al., 2016;
Rushulo et al., 2016; Senturk et al., 2012; Sofiene et al., 2015; Woman Trial Collaborators 2017;
Wong et al., 2010; Xu et al., 2012).
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Route of Administration
The mode of TXA administration may impact the drug’s influence on postpartum
bleeding. One article assessed oral TXA as a control for postpartum hemorrhaging. Diop et al.
(2020) conducted a double-blinded randomized study with 258 hemorrhaging women.
Participants in the experimental group were given a one-time dose of 1950 mg of PO TXA in
combination with 800 mcg of PO misoprostol and participants in the control group received a
placebo pill and 800 mcg of misoprostol. Diop et al. (2020) found oral TXA was an ineffective
form of hemorrhaging control. When compared to the experimental group, the control group
required similar amounts of additional uterotonics to stabilize bleeding (p = .59; Diop et al.,
2020).
Seven studies explored the effectiveness of TXA when administered intravenously (Bose
& Beegum, 2017; Durand-Zaleski et al., 2020; Gungorduk et al., 2013; Lakshmi, 2016; Ramesh
et al., 2015; Roy et al., 2016; Wong et al., 2010). Bose and Beegum (2017) conducted an
experimental study that included 163 women. The experimental group was given 500 mg of IV
TXA and the control group was given 600 mg of oral misoprostol. There were minimal
differences in patient outcomes between the experimental (470.30 ± 192.548) and control group
(491.74 ± 200.043 ml, p = 0.487). Specifically, there were minimal differences between the two
groups in postpartum hemoglobin and platelet levels (p = 0.197). Therefore, TXA was not
significantly superior to uterotonics.
The previous studies reviewed did not find TXA to be superior, however various studies
found the drug to be effective (Durand-Zaleski et al., 2020; Gungorduk et al., Lakshmi, 2016;
2013; Ramesh et al. 2015; Roy et al., 2016; Wong et al., 2010). Durand-Zaleski et al. (2020)
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conducted a randomized control trial consisting of 4,079 women. Women in the experimental
group received 1 g of TXA and women in the control group were given 1 g of sodium chloride.
Durand-Zaleski et al. (2020) found women in the experimental group required less intervention
for postpartum hemorrhaging (PPH) compared to the control group (RR = 0.74, 95% CI [0.61,
0.91], p = .04). Consistent with these findings, Gungorduk et al. (2013) found 1 g of IV TXA
improved PPH outcomes in a randomized control study with 454 women. That is, there were
fewer cases of PPH among the TXA group (261.5 ml) compared to the control group (349.98 ml,
p < .001).
In addition, more women in the control group needed supplementary uterotonics to
stabilize bleeding compared to women in the experimental group (RR = 3.18, 95% CI [1.29,
7.81], p = .007). Similarly, another randomized study found the group receiving TXA had less
blood loss (347.17 ml) from the time of placental delivery to compilation of the cesarean section
compared to the control group (517.72 ml, p < .001). Finally, Ramesh et al. (2015) also
supported IV administration of TXA in a randomized controlled study consisting of 200 women.
Findings showed significantly less blood loss in the experimental group 2 hr postpartum (M =
3.80 ml) compared to the control group (M = 112.25, p < .001) (p = .002).
Studies on IM TXA administration were also reviewed in the matrix. A randomized study
with 100 participants found IM TXA was effective during the birthing process (Roy et al., 2016).
Women in the experimental group received IM TXA and women in the control group received
IM sodium chloride. Results showed 22% of women in the control group needed additional
uterotonics compared to only 2% in the experimental group, a statistically significant difference
(p < .001).
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Topical use of TXA was also found to reduce bleeding. In a randomized control trial with
125 participants, Wong et al. (2010) investigated the effects of topical TXA in wound areas on
bleeding. Participants in the experimental group were given 1.5 to 3 g of TXA mixed with
normal saline while the control group was given normal saline to apply to their wounds. Results
showed a significant reduction in bleeding among the TXA group by 20% to 25% (p < .017),
significantly increasing hemoglobin levels by 16% to 17% (p < .017) compared to the control
group. Results from this study may be applied to understand the potential impact of TXA on
cervical, vaginal, and rectal lacerations.
According to the reviews regarding TXA routes the method of administration did impact
the efficiency of TXA. PO TXA was not found to effectively manage postpartum blood loss,
however, the IM route was found to be moderately effective (Diop et al., 2020; Roy et al., 2016).
While 78% of participants were adequately treated with IM TXA, the remaining 22% of
participants presented with unstable blood loss and therefore required further intervention to
reach equilibrium (Roy et al., 2016). However, IV TXA seemed the most effective blood
stabilizer for postpartum bleeding. Topical TXA use was also reviewed. Wong et al. (2010)
found topical TXA to be effective among bleeding wounds. Although this study was not specific
to birth-related lacerations these findings are significant to postpartum hemorrhaging as they are
relatable to vaginal, cervical, and anal wounds during the birthing process.
These studies had multiple strengths and weaknesses. First, Diop et al. (2020) clearly
defined postpartum hemorrhaging as at least 700 ml of bleeding and used computerized blocks to
sporadically classify patients into experimental and control groups. The computerized placement
of groups preserved the integrity of the double-blind study. Second, Bose and Beegum (2017)
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evaluated hemoglobin levels of each patient 48 hr prior to delivery and evaluated levels again
post-delivery to determine blood loss. Third, Durand-Zaleski et al (2020) evaluated a large
sample size of women (N = 4,079). Large sample sizes increase the likelihood that data are
generalizable to other populations and settings. Finally, low-risk and high-risk vaginal deliveries
were assessed in these studies to help midwives determine how different patients will react to the
drug (Gungorduk et al., 2013).
However, there were several limitations across these studies, including the standards for
blood loss measurements and the samples chosen for the studies. First, blood loss was
determined by visual measurements; therefore, there may be discrepancies in measurements of
blood loss (Gungorduk et al., 2013; Lakshmi, 2016). A few of the studies had a sample size of
only 100 women, so findings may not be generalizable to the majority of patients (Roy et al.,
2016; Wong et al., 2010). Furthermore, Roy et al. (2016) did not include participants with highrisk pregnancies; therefore, it is unknown whether TXA is effective among more vulnerable
populations.
Time of Administration
The time of administration may impact the ability of TXA to reach the desired therapeutic
effects. The WHO (2017) has suggested administering TXA within 3 hr of time of birth. Nine
articles explored the effectiveness of TXA when administered prophylactically prior to delivery
versus post-birth (Chandak et al., 2017; Gillissen et al., 2017; Gungorduk et al., 2013; Lakshmi,
2016; Rushulo et al., 2016; Sentilhes et al., 2018; Senturk et al., 2012; Sofiene et al., 2015;
Woman Trial Collaborators, 2017; Xu et al., 2012).
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In total, five studies supported the use of administering TXA prior to delivery (Chandak
et al., 2017; Lakshmi, 2016; Rushulo et al., 2016; Sofiene et al., 2015; Xu et al., 2012). Xu et al.
(2012) conducted a randomized study with 174 participants. Compared to the control group (84.7
± 80.2), the TXA group had lower rates of blood loss when bleeding was assessed 2 hr after csection (46.6 ± 42.7, p = .02). Therefore, the authors recommended administering TXA at least
10 min prior to cesarean births (Xu et al., 2012). Rushulo et al. (2016) also conducted a
randomized study that administered TXA to the experimental group 10 min prior to cesarean
section. Findings showed TXA was an effective form of bleeding control, with significantly
reduced bleeding in the experimental group compared to the control group (p < .001). Sofiene et
al. (2015) also supported the use of prophylactic TXA in an experiment with 52 low-risk
patients. The control group was given 10 ml of normal saline while the TXA group received 10
mg/kg 5 min prior to the first incision of the cesarean section. Overall, the authors found
significantly less mean blood loss in the TXA group compared to the control group (p = .017),
suggesting less oxytocin was needed in the TXA group (p = .05). Additionally, Chandak et al.
(2017) and Senturk et al. (2012) conducted randomized studies that also supported prophylactic
use of TXA2. Chandak et al. (2017) administered 1 g of TXA to the experimental group and
sodium chloride to the control group 5 min prior to the start of cesarean sections. Chandak et al.
(2017) found postpartum hemorrhaging occurred more often in the control group compared to
the experimental group (p = .049). Additionally, the control group lost more blood within 2 hr
after the cesarean section compared to the experimental group (p < .001). Senturk et al. (2012)
administered TXA 10 min prior to surgery. Senturk et al. (2012) also found a greater loss of
hemoglobin in the control group compared to the experimental group (p = .034). In a randomized
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control study, Lakshmi (2016) administered TXA 10 min prior to cesarean deliveries. Lakshmi
(2016) found only 9.3% of women in the experimental group experienced a 10% hemoglobin
compared to 39% of subjects in the control group (p < .01).
Four articles discussed TXA use within 3 hr of birth (Gillissen et al., 2017; Gungorduk et
al., 2013; Sentilhes et al., 2018; Woman Trial Collaborators, 2017). Women Trial Collaborators
(2017) is a randomized study with 20,000 participants ages 16 and above. The study was
completed in 193 hospitals across 23 countries (Woman Trial Collaborators, 2017). TXA was
found to improve mortality and morbidity risk when given within 3 hr of vaginal and cesarean
deliveries. Risk of death related to postpartum hemorrhaging decreased in women who received
TXA (RR = 0.81, 95% CI [0.65, 1.00], p = .045). There was an average of 1.2% hemorrhagerelated deaths among women in the TXA group compared to 1.7% in the control group (RR =
0.69, 95% CI [0.52, 0.91], p = .008) (Woman Trial Collaborators, 2017). Sentilhes et al. (2018)
supported these findings and found patients who received TXA 2 to 10 min after a vaginal birth
had lower rates of postpartum hemorrhaging (7.8%, p = .004) than those who did not (10.4%;
RR = 0.74, 95% CI [0.61, 0.91], p = 0.04). Gillissen et al. (2017) observed 1260 women above
the age of 18 from the Netherlands. Women were divided into three groups including early TXA
administration ( 1 hr post birth), late TXA administration (4 hr post birth), and the control group.
Gillissen et al. (2017) found patients treated with late TXA experienced more bleeding (1,300
ml) than the control group treated with oxytocin (800 ml). The incidence of hemorrhagic shock
was also higher in early admission 31% compared to late or no TXA administration 21%
(Gillissen et al., 2017). Contrary to Gillissen et al. (2017), findings from Gungorduk et al. (2013)
showed TXA was beneficial when administered within 3 hr of post-vaginal births. Specifically,
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Gungorduk et al. (2013) found significantly less blood loss in vaginal deliveries in the TXA
group (261.5 146.8, p < .001) than the control group (349.98 188.85 mL). The control group also
required more uterotonics than the TXA group (RR = 3.18, 95% CI [1.29, 7.81], p = .007).
Large study samples and extended study periods were strengths in a number of the
studies presented (Gillissen et al., 2017; Sentilhes et al., 2018; Woman Trial Collaborators,
2017). However, some limitations were present in the remaining studies, including small sample
sizes and short study terms (Gungorduk et al., 2013; Rushulo et al., 2016; Sofiene et al., 2015;
Xu et al., 2012). Xu et al. (2012) conducted their study in a grade IIIA hospital, so different
findings may emerge in suboptimal settings. Additionally, participants were randomized using
sealed envelopes instead of electrical data which may cause errors in the randomizing process
(Xu et al., 2012). Lakshmi (2016) reported failure to assess long-term effects of TXA as a
limitation.
Hemorrhaging Risk Factors
The previous health of the mother and mode of delivery may impact the extent of
postpartum bleeding. The articles reviewed in this section assessed risk factors for PPH and the
impact of TXA on these high-risk patients. One prospective cohort study with 1,188 participants
reviewed the risk associated with hemorrhaging between vaginal and cesarean deliveries
(Ononge et al., 2016). Postpartum hemorrhaging was defined as bleeding over 500 ml.
Hemorrhaging risk factors were greater in vaginal deliveries among mothers who had
macrosomia deliveries (aOR = 2.14, 95% CI [1.02, 4.47], p= 0.01 ) or HIV positive sero-status
(aOR = 2.26, 95% CI [1.20, 4.25], p = 0.03), including vaginal multiples (aOR = 2.26, 95% CI
[0.58, 8.79], p = 0.02). However, women having cesarean deliveries were at greater risk for
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hemorrhaging than vaginal births (aOR = 7.54, 95% CI [4.11, 13.81], p <0.001). These findings
are significant for identifying patients in greater need of TXA management.
Research has also found anemia is a risk factor for hemorrhaging. Goswami et al. (2013)
conducted a randomized control study consisting of 90 anemic patients with hemoglobin levels
between 7-10 g. Participants had cesarean sections scheduled and were either randomized into
Group 1 who received 10 mg/kg of TXA, Group 2 who received 15 mg/kg of TXA, or Group 3
who received a placebo. TXA and placebos were administered 20 min prior to the start of the
cesarean delivery. Group 1 experienced 377 ml of blood loss, Group 2 experienced 261 ml of
blood loss, and Group 3 experienced 527 ml of blood loss. Therefore, TXA was found to reduce
blood loss among anemic patients during cesarean section (Goswami et al., 2013).
Roberts et al. (2013) also assessed risk factors for hemorrhaging. However, this study
specifically examined the benefits of TXA among 20,211 operative and trauma patients in a
randomized control trial. Roberts et al. (2013) found TXA was an effective treatment option for
trauma patients and therefore supported the use of TXA among at-risk and trauma patients.
Specifically, participants in the TXA had significantly lower mortality and morbidity rates (M=
1,463, 4.5%) compared to the control group (M= 1,613, 16%; RR = 0.91, 95% CI [0.85, 0.97], p
= .004). Findings from this study can be used to predict the need and effectiveness of TXA
among women who experience vaginal trauma from cesarean deliveries and vaginal births.
Delivery mode was found to have significant impacts on a patient’s risk for bleeding and
need for TXA therapeutics. Ononge et al. (2016) determined that mothers who suffer from
comorbidities prior to pregnancy are at greater risk of unstable postpartum bleeding. Significant
amounts of postpartum bleeding were observed among mothers who had HIV, diabetes, or
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macrosomia births (Ononge et al., 2016). Additionally, anemic patients were found to be
predisposed to hemorrhaging post-delivery (Goswami et al., 2013). Patients delivering via
cesarean section were at greatest risk for postpartum bleeding when compared to high- and lowrisk vaginal births (Ononge et al., 2016). However, Goswami et al. (2013) and Roberts et al.
(2013) found TXA to be a therapeutic option for the maintenance of postpartum hemorrhaging
among patients with predisposed risk for unstable postpartum bleeding.
Multiple strengths and weaknesses were discovered among the reviewed studies. Ononge
et al. (2016) included a large sample size of 1,188 women. Roberts et al. (2013) also had a large
sample size of 20,211 participants. The sample sizes found in Ononge et al. (2016) and Roberts
et al. (2013) are significant as the sample sizes are generalizable to the general population.
Second, Ononge et al. (2016) assessed the use of TXA across multiple types of deliveries,
including various types of vaginal and cesarean births, therefore, the risk for hemorrhaging was
observed among a diverse patient population. These studies also included a number of limitations
related to experiment location and sample size. First, the Ononge et al. (2016) study was
conducted in Uganda; as such, the study did not assess the impacts of TXA on various
populations and ethnic groups and findings may therefore be limited to patient populations in
Uganda. Second, Goswami et al. (2013) included a relatively small sample size in their study
which may limit generalizability.
Potential for Adverse Effects
Numerous studies have acknowledged the potential risk associated with the use of TXA,
particularly concerning adverse neonatal effects and maternal thrombosis development,
therefore, it is important to explore TXA safety concerns (Chandak et al., 2017; Gilad et al.,
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2014; Ramesh et al., 2015; Sentilhes et al., 2018). Three studies assessed the potential for
adverse effects among neonatal development and risk for thrombosis among mothers given TXA
(Gilad et al., 2014; Ramesh et al., 2015; Sentilhes et al., 2018).
Gilad et al. (2014) reviewed adverse effects of TXA in the newborn. Gilad et al. (2014)
conducted a prospective, controlled observational study with 21 women in the experimental
group and 42 women in the control group. The experimental group consisted of women who
received TXA during their pregnancy or postpartum period. Women (N =63) in the experimental
and control groups received a follow-up telephone interview regarding neonatal symptoms,
production of breastmilk, and newborn outcomes at 1 to 3 years of age. Gilad et al. (2014) found
one mother in the experimental group had lower milk production compared to the control group,
however, this finding was not statistically significant (p = 1.00). Another mother in the
experimental group reported infant restlessness, while one mother in the control group reported
gastroesophageal reflux (p = 1.00). One child from the experimental group showed weight below
the third percentile compared to four children in the control group (p = 0.66). Gilad et al. (2014)
did not find statistical significance between adverse effects found between the experimental and
control group. Therefore, no adverse effects related to TXA were found among newborns.
Ramesh et al. (2015) supported these findings in a randomized study of 200 women and found
no significant differences in newborn appearance, pulse, grimace, activity, and respiration
(APGAR) scores between women in the experimental and women in the control group (p =
0.50).
Sentilhes et al. (2018) reviewed the thromboembolic effects of TXA in a randomized
control trial of 4,079 women having vaginal births. Sentilhes et al. (2018) found TXA did not
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increase the risk for thromboembolic episodes among women in the study group (0.1%)
compared to women in the control group (0.2%; RR = 0.25, 95% CI [0.03, 2.24], p = 0.37).
However, Sentilhes et al. (2018) found TXA increased the risk of mild vomiting episodes among
the TXA group when compared to the control (P<0.001).
In summary, empirical evidence has demonstrated little potential adverse effects of TXA
administration. There were no statistical differences found between newborns exposed to TXA
through breastfeeding compared to those without TXA exposure (Gilad et al., 2014). Therefore,
TXA has not been found to significantly and negatively impact neonatal health or development
(Gilad et al., 2014). Likewise, TXA was not found to significantly increase risk for developing
thromboembolic episodes (Sentilhes et al., 2018). However, TXA may cause mild
gastrointestinal discomfort during use (Sentilhes et al., 2018).
Various strengths and limitations can be observed from the studies reviewed. Ramesh et
al. (2015) and Sentilhes et al. (2018) included large sample sizes in their studies, as a result these
finds are relatable to the general population. An additional strength was that Gilad et al. (2014)
conducted the experiment for 3 years which allowed researchers to observe the impacts of TXA
on the neonate into childhood. However, a limitation was that Gilad et al. (2014) was a pitetit
study of 63 participants meaning the results found may not reflect the general population.
Resources
Cost and availability must be addressed when implementing TXA into a medical
institution. As mentioned earlier, postpartum hemorrhage significantly contributes to maternal
mortality. It is essential that health care workers find effective and cost-conscience interventions
that can be used across the globe. Two articles assessed the cost implications of TXA in

35
obstetrical care (Durand-Zaleski et al., 2020; Roberts et al., 2013). In both studies, TXA
administration was found to be cost effective for medical institutions. First, Roberts et al. (2013)
found mortality and morbidity rates significantly decreased in patients who received TXA within
3 hr of trauma (M= 1,463, 14.5%) compared to patients who did not receive TXA (1,613, 16%;
RR = 0.91, 95% CI [0.85, 0.97], p = .004). Therefore, hospitals were able to make significant
financial savings among patients who received TXA treatment. Roberts et al. (2013) determined
the incremental cost for administering TXA versus not administering TXA was $48,002.
Therefore, the incremental cost per life year was $68 (Roberts et al., 2013). Further, TXA
administration saved 755 life years for every 1,000 patients in the United Kingdom (Roberts et
al., 2013). Durand-Zaleski et al. (2020) also supported the cost effectiveness of TXA for
patients. When TXA and non-TXA patients giving birth vaginally were compared, TXA patients
spent an average of $7,497 compared to an average of $9,945 for non-TXA patients (DurandZaleski et al., 2020). The control group also spent more money on blood products. In total, the
control group spent an average of $10,061 on additional medications and blood products
compared to $6,037 spent among the TXA group.
The assessed articles demonstrate that TXA is a cost effective treatment option. DurandZaleski et al. (2020) and Roberts et al. (2013) report TXA to be an economical option for patients
and medical institutions.Therefore, it is financially feasible to make TXA available to midwives
and patients in low income communities and underdeveloped countries.
Summary
Twenty articles were reviewed to investigate the impact of TXA on postpartum bleeding.
The majority of included articles were randomized control studies. The articles included in the
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literature appraisal were classified as either strong or good quality based on the Johns Hopkins
research evidence appraisal tool. The reviewed research supported TXA given prior to delivery,
within 3 hr of delivery, and after a postpartum hemorrhage has occurred can effectively minimize
postpartum hemorrhaging. Research has also shown TXA is a cost effective drug and is therefore
available to midwives in developing countries.
Chapter 4 will discuss implications for nurse midwifery practice and the need for further
research. Finally, Kurt Lewin's (1951) theory will be used to explore how to integrate TXA use
into midwifery care.
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Chapter 4: Discussion, Implications, and Conclusions
The purpose of this literature appraisal is to determine the function of TXA for
maintaining postpartum bleeding. Twenty scholarly articles were selected and assessed using the
John Hopkins research appraisal evidence tool. Chapter 4 explores trends and gaps in the
literature, implications for midwifery practice, and provides recommendations for future
research. In addition, Kurt Lewin’s (1951) theory is applied to the integration of TXA in
midwifery practice.
Literature Synthesis
The research question that informed this literature review explored the impact TXA has
on postpartum bleeding during the third and fourth stages of labor. In conclusion, the body of
research reviewed found TXA was an effective treatment option for maintaining postpartum
bleeding. Treatment modalities included assessment of route and time of TXA administration.
Multiple outcome factors were taken into consideration including, hemorrhaging risk factors,
adverse effects, and resources associated with TXA use were assessed. Since scholarly articles
explored the effect of TXA via multiple routes, it is vital to identify the most effective forms of
TXA administration. Furthermore, significant connections were made across research in regard
to when TXA should be administered around time of birth. While some articles supported
prebirth administration, other articles advocated for the use of TXA within 3 hr of birth (Woman
Trial Collaborators, 2017; Xu et al., 2012).
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Trends and Gaps in Literature
Route of Administration
Multiple themes were established in the section on route of administration. The TXA
administration routes explored included oral, intravenous, IM, and topical administration (Bose
& Beegum, 2017; Diop et al., 2020; Durand-Zaleski et al., 2020; Gungorduk et al., 2013;
Lakshmi, 2016; Ramesh et al., 2015; Roy et al., 2016; Wong et al., 2010). A number of TXA
routes were explored to determine its effectiveness across multiple settings including home,
hospital, and in-center births that may require various forms of TXA (Diop et al., 2020). Diop et
al. (2020) concluded TXA maintained postpartum bleeding at significantly greater levels
compared to uterotonics. While 56.9% of the TXA group required additional uterotonics, 60.2%
of the control group received supplementary uterine control. In all, the average blood loss in both
the experimental and control groups was 700 ml (Diop et al., 2020).
A number of studies assessed blood loss among postpartum patients given IV and IM
TXA. These forms of TXA use are ideal for hospital and birthing center deliveries where IV and
IM administration are feasible (Gungorduk et al., 2013). Only one study found IV TXA was
ineffective (Bose & Beegum, 2017), while the majority of scholarly articles found IV TXA was
effective and therefore supported the use of IV TXA (Durand-Zaleski et al., 2020; Gungorduk et
al., 2013; Lakshmi, 2016; Ramesh et al., 2015). Lakshmi (2016) concluded when TXA was
incorporated intravenously in care, only 9.6% of women required subsequent bleeding control
while 39% of women not given TXA needed additional assistance to stabilize bleeding during
the postpartum stage. IM TXA was also found to promote stabilized postoperative hemoglobin
values. Roy et al. (2016) also found postoperative hemoglobin drop levels around 0.2% g among
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participants in the experimental group and around 0.7% gm among participants in the control
group.
Furthermore, topical TXA was explored due to its availability for home, hospital, and
birthing center births. Wong et al. (2010) found topical TXA was effective among wound trauma
patients. That is, patients who received TXA displayed 16% to 17% higher hemoglobin levels
compared to patients who received alternate treatment. However, a gap in the Wong et al. (2010)
experiment was that it did not specifically study the effectiveness of TXA among birth related
lacerations. Therefore, further research is needed to verify therapeutic response to topical TXA
when used in obstetrics.
Time of Administration
Understanding the significance of the timing of TXA administration is important as it will
influence the therapeutic effects of the drug. A number of studies have argued TXA is most
effective when administered prior to delivery (Chandak et al., 2017; Lakshmi, 2016; Rushulo et
al., 2016; Sofiene et al., 2015; Xu et al., 2012). However, other scholarly sources have argued
TXA is most effective when given within 3 hr of delivery (Gillissen et al., 2017; Gungorduk et
al., 2013; Sentilhes et al., 2018; Woman Trial Collaborators, 2017). Timing of TXA
administration is vital to explore as it will enable midwives to appropriately choose when to
administer TXA. According to scholarly articles explored in this literature appraisal, TXA has
shown remarkable effects on preserving blood loss when administered any time prior to 3 hr
post-birth (Chandak et al., 2017; Gillissen et al., 2017; Gungorduk et al., 2013; Rushulo et al.,
2016; Sentilhes et al., 2018; Senturk et al., 2012; Sofiene et al., 2015; Woman Trial
Collaborators, 2017; Xu et al., 2012). However, a gap in literature remains on whether TXA
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should be administered as a single dose or at various times throughout treatment. Further
research is needed to determine if TXA is most effective when given in multiple doses as
opposed to one single dose (Chandak et al., 2017).
Hemorrhaging Risk Factors
Risk for hemorrhaging was explored to identify which patients were at greater risk of
experiencing postpartum hemorrhages and determine the success of TXA among at-risk
populations, including patients with HIV, anemic patients, and cesarean patients. Women giving
birth to macrosomic newborns were also classified as an out-risk patient population (Ononge et
al., 2016). Findings across articles supported the use of TXA among patients at risk for
hemorrhaging (Goswami et al., 2013; Roberts et al., 2013; Ononge et al., 2016). While Ononge
et al., 2016) explored which patients were at greater risk for postpartum hemorrhaging the study
was limited to Uganda. Therefore, the effectiveness of TXA among various ethinic groups
remains a gap in literature.
Adverse Effects
Potential adverse effects of TXA were explored to determine safety concerns in TXA
administration. Xu et al. (2012) recommended avoiding TXA prior to delivery due to potential
negative impacts on the unborn fetus. However, other scholarly articles that explored the adverse
impact of TXA found no detrimental effects on development, feeding, or stability of health
among newborns whose mothers received TXA (Gilad et al., 2014; Ramesh et al., 2015).
However, potential adverse effects of TXA on women with cardiovascular, stroke, or clotting
diseases remains a gap in literature (Sentilhes et al., 2018).
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Implications for Midwifery
The midwifery community is significant for ensuring safe pregnancies and births.
Research has found TXA to be an effective option for the prevention of postpartum
hemorrhaging. Therefore, routine use of TXA should be implemented into the active
management of postpartum care. It is imperative midwives understand the positive impact TXA
can have on women at the time of birth. The core competencies of midwifery encourage
midwives to seek and establish their care according to the most current medical standards
(ACNM, 2017). Therefore, the ACNM (2017) supports the appliance of TXA into midwifery
practice. Including TXA in midwifery practice may significantly reduce experiences of
hemorrhaging among women. In fact, 4.8% of all home and clinic births without the use of TXA
in obstetrics have resulted in emergent hospital transfers related to blood loss (Mielke &
Obermeyer, 2020). Deregulation in the patient's coagulation and fibrinolytic systems occurs
during a postpartum bleed exceeding 1000 ml, resulting in an exhaustion of platelets and
fibrinogen. However, TXA has been found to limit postpartum bleeding and maintain maternal
stability through its antifibrinolytic factors (Mielke & Obermeyer, 2020).
It is feasible to implement TXA into midwifery practice. TXA is an economical drug that
can be made available to areas and patients suffering from limited medical and financial
resources. Durand-Zaleski et al. (2020) strongly advocated for TXA use among low-income
areas and developing countries. The authors also found TXA was 65% to 73% more cost
effective when compared to traditional uterotonics. Therefore, TXA may improve maternal
outcomes on a global scale (WHO, 2017). The midwifery code of ethics, which instructs
midwives to promote equality and access to care among all women,
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also supports the use of TXA in underdeveloped areas (ACNM, 2020).
Recommendations for Future Research
Future research needs to be conducted on the effectiveness of TXA during the postpartum
period. Treatment modalities reviewed in this literature appraisal included route and time of
administration, hemorrhaging risk factors, and potential adverse effects. Moreover, this literature
review found IV, IM, and topical TXA administration to be effective treatment options for
bleeding control. However, further research is needed to determine the safety and effectiveness
of topical TXA on third- and fourth-degree cervical lacerations. Also, future studies should
examine appropriate time of topical administration.
Research has shown TXA is effective across a number of vulnerable populations.
However, patients suffering from blood clotting disorders or chronic disease have traditionally
been excluded from TXA studies. However, it is vital to explore the safety and potential risk of
TXA for high-risk women, such as women with high-risk pregnancies.
TXA is cost effective and therefore ideal for low-income populations and developing
countries. Further research must explore the most cost efficient and effective form of TXA. For
example, some studies found IM TXA used to be more effective than oral TXA medication (Diop
et al., 2020; Roy et al., 2016). Therefore, further studies are needed to explore the ability for
underdeveloped countries and communities to afford IM TXA, clean needles, and syringes.
Research should also examine the ability for these communities to safely discard syringes.
Due to the cost effectiveness and health benefits of TXA, ACOG (2020) may explore the
benefits of removing TXA from the second stage of the algorithm and including it in the first
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stage for postpartum hemorrhaging. TXA may decrease the need for hemorrhaging patients to
receive further treatment or blood products.
Integration of Kurt Lewin’s Theory
Midwives who achieve the unfreezing stage may be more likely to acknowledge the need
for continuous updates in women's services. The purpose of unfreezing is to encourage providers
to continuously seek change in a medical institution to address the changing needs of patients
(Hussain et al., 2018). Unfreezing is particularly important because, regardless of the medical
standards established today, maternal hemorrhaging remains a significant concern (Alam &
Choi, 2015). During the unfreezing stage, midwives have the responsibility to recognize the need
for adjustment in the current midwifery practice (Hussain et al., 2018). After determining the
need for change, midwives should first predict variables associated with change. Related to this
study, midwives are responsible for predicting the impact TXA will have on women and medical
institutions. There are a few possible predictions that could be made on the effects of TXA. First,
the use of TXA may improve maternal outcomes by decreasing morbidity and mortality rates
associated with postpartum hemorrhaging. Second, TXA use could positively impact medical
institutions (Hussain et al., 2018). More specifically, the cost efficiency of TXA may reduce the
financial burden for medical organizations and increase the likelihood TXA is incorporated into
routine care. This is particularly important to consider for low-income communities and
underdeveloped countries (Alam & Choi, 2015).
After all major factors are considered, change is implemented in the second stage. During
this stage, medical staff alters their original thoughts, feelings, and actions to adapt to a new plan
of care (Hussain et al., 2018). At this time, the organization will begin training staff members to
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safely and appropriately implement change. As it relates to the present study, midwives would be
educated on the routes, doses, and times that TXA could be safely administered. When teaching
is complete, medical professionals are encouraged to share their experiences (Hussain et al.,
2018). Knowledge sharing between experts and novices can strengthen the confidence and
performance of midwives unfamiliar with the prophylactic use of TXA (Hussain et al., 2018).
Refreezing is the final step considered in Lewin's change theory. During refreezing, the
organization establishes the change as the new standard of care (Hussain et al., 2018). The
midwife's organization will develop set facility policies on the use of TXA, such as the
appropriate routes, times, and dosages of TXA administration (Hussain et al., 2018). Refreezing
is critical for preventing medical staff from reverting to former standards of care (Shirey, 2013).
Lewin’s et.al., (1951) theory facilitates the implementation of prophylactic use of TXA in
maternal care. The theory will aid in improving steps toward medical changes. Lewin's theory
also promotes confidence among midwives as changes are made to control maternal bleeding
(Hussain et al., 2018). Altogether, Lewin's theory will improve the transition to enriched methods
of care.
Conclusion
The pertinent findings of this critical review included the route of TXA administration,
the time of TXA administration, risk factors for hemorrhaging, adverse effects related to TXA,
and resources. These factors have been found to significantly impact the efficiency of TXA
during the postpartum period. For the purpose of this literature appraisal twenty scholarly articles
were reviewed using the Johns Hopkins Research Evidence Appraisal Tool with statistically
significant results for TXA administration, risk factors for hemorrhaging, adverse effects related
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to TXA, and resources. The route of TXA administration influences drug efficiency while the
time of TXA administration impacts the therapeutic effect of TXA. Hemorrhaging risk factors
impact which patients are ideal for TXA treatment and drug efficiency. However, adverse effects
impacts and the side effects associated with TXA use. Resources influence cost and availability
of TXA in underdeveloped communities.
Nurse midwives are at a substantial position to implement TXA into obstetrical care.
Nurse midwives’ prominent roles in women’s services, birth and newborn care give midwives
significant influence on TXA integration into women’s services. Application of Kurt Lewin’s
Theory facilitates TXA use within midwifery services and demonstrates the necessary steps
needed to incorporate TXA into current practice. By practicing according to up to date evidence
midwives can safely incorporate TXA into current standards of postpartum care to stabilize and
maintain equilibrium during the postpartum period.
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Purpose:
To compare the
efficiency of
sublingual
misoprostol to TXA
during C-section

Low risk TXA
patients had lower
blood loss than
The control group
control group 416 ml
received 600mg of
vs 505 ml, (p =
oral misoprostol while 0.023).
The TXA
(independent ) group Patients who were
received 500mgof IV high risk did not have
Sample/Setting:
TXA.
a difference in blood
163 women who were
loss between the two
between the ages of
Blood loss was
groups (534 vs 478
18 to 39 years old
visually measured. Hb mL, ( p = value 0.23)
having a singleton
and platelet labs were
delivery. Patients
examined prior to
Over all little
were scheduled or had surgery then 48 hours significant difference
emergency c-sections post op to determine
between independent
in the Department of blood loss.
and control group
Obstetrics and
(470.30 ± 192.548 vs
Gynecology of the
491.74 ± 200.043 mL,
Malabar Institute of
(p = 0.487)
Medical Sciences,
Calicut, Kerala and
Little difference
India.
between Hb and PCV,
(p =0.197)]

Johns Hopkins
Evidence Appraisal:

Randomized study

Need for additional
uterotonics were
similar in both groups
(p = 0.957)

Strength:l
Conclusion:
Quality: Good
TXA is effective in
low risk patients
however it appears to
be less effective in
high risk patients

Strengths:
The article addressed
cost efficiency of
TXA
Side effects of TXA
such as nausea,
vomiting and
shivering were
discussed
Hb and PCV were
assessed before and
after delivery.

Limitations:
The sample size was
small therefore
finding may not be
relatable to the
general public.
Blood loss was not
measured
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Author Recommendations: TXA should be administered after cord clamping. TXA is most
effective in high risk patients. TXA should be administered to high risk patients with scheduled
or emergent c-sections.
Implications: Midwives may suggest the use of TXA for low risk patients that have a failed
trial of labor. TXA may effectively decrease blood loss among c-section patients. Post-op,
midwives should assess TXA patients for NV and shivering.
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Source:
Chandak, A., Gupta, I., & Sreemayi, C. (2017). Efficacy of tranexamic acid in decreasing
blood loss during and after cesarean section: A randomized case controlled prospective
study. International Journal of Science and Research, 6(1),1321–1323. https://doi.org/
10.21275/art20164292
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Purpose:
To determine the
ability for TXA to
limit postpartum
bleeding among csection patients
Sample/Setting:
The sample consisted
of 100 women
scheduled for
cesarean deliveries

Johns Hopkins
Evidence Appraisal:
Strength:1
Quality: Good

Strengths:
Randomized case
controlled study.
1g of TXA was given
over 5 minutes prior
to the c-section
incision while the
control group
received sodium
chloride
Hemoglobin and
hematocrit levels
were reviewed one
day prior to cesarean
section and agin post
op.
Blood loss was
measured by
assessing blood
present in the suction
tubes after the
delivery of the
placenta. Pads and
linien were also
weighed for blood
from the completion
of c-section time to 2
hours post delivery

There was significant
blood loss in control
from time of delivery
of placenta to end of
c-section (P =
0.0001).
There was also
significantly more
blood loss in control
from end of c-section
to two hours
postpartum

Hemoglobin was
reviewed one day
before and again after
c-section to
demonstrate blood
loss in each individual
patient
Exact measurements
were taken for blood
loss

Study group had less
cases of postpartum
hemorrhaging (P =
0.049)

Qualifications for
postpartum
hemorrhaging was
defined for the
purpose of this study

Conclusion:

Limitations:

TXA effectively
controls bleeding in
cesarean patients

The sample size was
small
The setting of the
study was not clearly
stated
Mothers with high
risk pregnancies or
high risk for PPH
were excluded from
the study

Author Recommendations: The author acknowledges increased risk for thrombosis in
pregnancy and therefore recommends further research to determine potential thrombosis risk
related to TXA administration.
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Implications: Midwife may order TXA for patients requiring to get c-sectioned. TXA may also
be considered for vaginal lacerations and bleeding.
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Source:
Diop, A., Abbas, D., Ngoc, N. T., Martin, R., Razafi, A., Tuyet, H. T., & Winikoff, B. (2020). A
double-blind, randomized controlled trial to explore oral tranexamic acid as adjunct for
the treatment for postpartum hemorrhage. Reproductive Health, 17(1),
https://doi.org/10.1186/s12978-020-0887-2
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Purpose:

This was a double
blinded randomized
To assess the
study which took
efficiency of oral
place between
TXA when given with October 25, 2016 to
misoprostol.
January 19, 2018. The
experiment included
258 participants who
Sample/Setting:
had vaginal deliveries.
258 women from four All the women in this
hospitals within
study were
Vietnam and Senegal experiencing
who were diagnosed
postpartum bleeds.
with postpartum
Postpartum bleeding
hemorrhaging
was classified as
bleeding over 700ml.
Johns Hopkins
Evidence Appraisal: Women with a history
of thrombosis or
Strength: l
medical
contraindications to
Quality: Good
TXA were excluded.
After delivery a
plastic drape and
calibrated funnel was
placed under the
maternal buttocks for
30 minutes post
delivery. Women
diagnosed with
hemorrhaging were
placed into the TXA
group or a placebo
group.
Women who received
TXA were given
1950mg of oral TXA
and 800mcg of po
misoprostol. women
in the control group
received a placebo
and 800 mcg of
misoprostol.

Control group
required less
additional uterotonics
than TXA group (p =
0.59)

Strengths:
The study was double
blinded which
preserved the integrity
of the experiment.

Moe participants from
the TXA group
Women in the TXA
required additional
group and placebo
uterotonics p = 0.51) group were both
properly treated for
postpartum
Conclusion:
hemorrhage within 30
minutes of
hemorrhaging.
PO TXA may not be
effective in treating
Computerized data
postpartum
was used to
hemorrhaging.
randomize
participants and
International
treatment options.
guidelines
recommend TXA IV
as standard
hemorrhage
Limitations:
treatment.
1950mg PO of TXA
was given when the
max dose is 2000mg
PO.
The study only had
258 participants.
Findings may be
different with a larger
sample size.
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Author Recommendations:
The Study also discloses other experiments have found TXA to be more effective when given 3
hours postpartum. However, the author recommends that PO TXA may be less effective than
IV TXA. Therefore, IV TXA should be given in times of a postpartum hemorrhage. Further
studies should be done to determine treatment options for postpartum hemorrhages when IV
access is not possible.
Implications: Midwives could consider administering TXA to treat postpartum hemorrhaging
and improve patient outcomes. However, PO TXA was not found to be an effective treatment
for postpartum bleeding, therefore, IV TXA should be given in conjunction with other
uterotonics within 3 hours of birth time for best outcomes.

Source: Durand-Zaleski, I., Deneux-Tharaux, C., Seco, A., Malki, M., Frenkiel, J., &
Sentilhes, L.
(2020). An economic evaluation of tranexamic acid to prevent postpartum haemorrhage
in women with vaginal delivery: The randomised controlled TRAAP trial. An
International Journal of Obstetrics & Gynaecology, 128(1), 114–120.
https://doi.org/10.1111/1471-0528.16456
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Purpose:
To estimate cost
effectiveness of TXA
for treatment of PPH

Strengths:

Randomized control
trial
1g of TXA given
intravenously in
Sample/Setting:
independent group
after prophylactic use
4079 women who had of oxytocin 10 min
vaginal deliveries
post delivery
throughout France
Women in the control
Johns Hopkins
group received
Evidence Appraisal: intravenous placebo
after prophylactic
Strength: l
dose of oxytocin.
Quality: Strong

PPH was defined as
bleeding more than
500ML collected by
collector bag

TXA and control
groups were not found
to have significant
differences in
bleeding of at least
500 ml (RR = 0.83,
95% CI [0.68–1.01],
P = 0.07)
However TXA group
had lower rates of
intervention for PPH
(RR = 0.74; 95% CI
[0.61–0.91],
P = 0.04)

The economic
analysis was done for
three months which
allowed researchers to
assess potential
readmissions and
financial burdens
The sample size was
large making the
study findings
generalizable

Limitations:
The average length of Only hospital costs
hospital stay was
could be studied.
3.66 1.3 days and the
total costs $2283, 399 The study was done in
Cheers guidelines
where used to
a high income setting
The
total
cost
of
determine cost
therefore low income
blood
products
was
efficiency
areas were not
$6,037
assessed
and $10,061 in the
Cost of delivery was
TXA and control
recorded in CRF
The study was done in
groups, respectively
including delivery
France, meaning the
suite, blood
cost of treatment in
141 patients in the
production and cost of
other countries was
TXA group versus
pre and post delivery.
not determined.
189 in
Bootstrap hypothesis
the control group, for
testing used to
a total of $7,497 and
compare costs by
$9,945, respecrandomisation group
tively
(tranexamic
acid versus placebo)
TXA group had
and by outcome
systematically lower
(postpartum haemorcosts than women in
rhage versus no
the control group,
postpartum
although no
haemorrhage)
statistically significant
dif-
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Author Recommendations:
The author recommends TXA be given proholaticly with oxytocin. They determine the
prophylactic use of TXA will improve patient outcomes and also decrease cost in hospital stay.
Implications: The midwife may consider TXA use particularly for her at risk patients.
MIdwives may also begin to consider TXA in low income areas and underserved countries due
to its cost efficiency.

Source: Gilad, O., Merlob, P., Stahl, B., & Klinger, G. (2014). Outcome following tranexamic
acid exposure during breastfeeding. Breastfeeding Medicine, 9(8), 407–410. https://doi.org/
10.1089/bfm.2014.0027
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Purpose:
To determine adverse
facts related to TXA
An observational
administration during study
pregnancy or lactation
Beilinson Teratology
Information Service
(BELTIS was used to
Sample/Setting:
interview mothers
who had TXA
63 postpartum women exposed to their
in Israel
newborn through
breast milk. These
women were observed
Johns Hopkins
for up to three years
Evidence Appraisal: for adverse effects
Strength: llI
Quality: Good

Data on lactation,
neonatal symptoms,
and outcomes at the
age of 1-3 years were
obtained.

Strengths:
One women from the
study group reported a Study continued for
decrease amount of
three years
breast milk (p = 1.0)
Limitations:
One participant in
study group reported There was a small
infant restlessness (p sample size
= 1.0)
Patients may have
Growth percentile
been bias when
below 3% was found answering questions
in one newborn in the regarding amount of
study group and four breastmilk and infant
newborn in the
restlessness
control (p = 0.66)
Study was not a RCT
Conclusion:
TXA had no
significant adverse
effects on mothers
and newborn

Author Recommendations: More research is needed to determine side effects of TXA.
Further research should be done one a large sample.

Implications: Midwives may consider prophylactic TXA in healthily women minimal side
effects have been found among newborns. Therefore, midwives can safely administer TXA
prophylactically prior to birth or after.
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Source:Gillissen, A., Henriquez, D. D., Akker, T. V., Caram-Deelder, C., Wind, M., Zwart, J.
J., & Bom, J. G. (2017). The effect of tranexamic acid on blood loss and maternal outcome in
the treatment of persistent postpartum hemorrhage: A nationwide retrospective cohort study.
Plos One,12(11), e0187555. https://doi.org/10.1371/journal.pone.0187555
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Purpose:
To determine if TXA
is more effective at
improving mortality
and mobility rates
than when given
within the first three
hours of a postpartum
bleed compared to
later or no TXA
administration .

Strengths:
This was a Quasiexperimental study.

The experiment was
reviewed and
approved by the
Ethical Committee of
the Leiden University
Medical Center
therefore, the
participants did not
need to give informed
Sample/Setting:
consent. This was a
retrospective cohort
study. Meaning the
The sample size
researchers
consisted of 1260
retrospectively
women (18 years old collected data of their
or older) from the
participants between
Netherlands who were Jan 1st 2011 to Jan 1st
experiencing
2013. The researchers
postpartum
then used cross
hemorrhages. The
referencing electronic
participants also had
data to identify
to receive four units
participants. Final
of red blood cells,
blood loss was
plasma or platelets to collected by
be part of the study.
measuring soaked
This experiment took gauze and
place within 61
examination of the
hospitals in the
collector/suction
Netherlands (Gillissen systems. The control
et al., 2017).
group was women
who did not receive
TXA while the
Johns Hopkins
intervention group
Evidence Appraisal: was those who
received TXA within
Strength:ll
three hours of a
postpartum bleed.
Quality: Strong

A strength is that the
Women who received experiment was done
TXA within the first
for two years and had
three hours bled more a large sample size.
than the participants
This makes the results
who did not.Those
from the experiment
who received TXA
more trustworthy.
within the first 3
Meaning the findings
hours bled at a rate of can be used for the
24ml vs 19ml/min and general public.
had an average of
1300ml vs 800ml of
blood loss. However, The experiment was
no difference in
approved by the
mortality rates were
Ethical Committee of
found between the
the Leiden University
two groups.
Medical Center which
ensures that patient’s
rights are not violated.
The incidence of
hemorrhagic shock
The authors were also
was also higher in
clear about qualifying
early of TXA
factors such as
admission 31%
women had to receive
compared to late or no at least four units of
TXA administration
red blood cells and be
21%
over 18 years old to
participate in the
study.
Conclusion:

Limitations:
The researchers
believe that early
TXA use in developed
countries may not be
as beneficial as it has
been found to be in
third world settings.

A limit is that health
prior to the
hemorrhage was not
considered during the
experiment.
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Author Recommendations: TXA may partially block degradation of the fibrin clot, however,
it is more effective to solve the cause of a postpartum hemorrhage than to immediately treat the
patient with TXA. TXA may be more useful in the case of a persistent postpartum hemorrhage.

Implications: As a provider I should consider all the possible reasons that a patient may be
having a hemorrhage. After treating the underlying cause of the bleed additional medications
such as TXA may be considered.

Source:
Goswami, U., Sarangi, S., Gupta, S., & Babbar, S. (2013). Comparative evaluation of two
doses
of tranexamic acid used prophylactically in anemic parturients for lower segment
cesarean section: A double-blind randomized case control prospective trial. Saudi
Journal of Anaesthesia, 7(4), 427–431. https://doi.org/10.4103/1658-354x.121077
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Purpose:

Strengths:

Hemodynamic
To determine
Double blind
parameters including
effectiveness of TXA randomized
pulse rate, blood
when given to anemic experiment from 2009 pressure, respiratory
women during the
to 2011
rate and SpO2 were
birthing process
Women were
found to be
randomized into
comparable after
Sample/Setting:
groups including :
statistical analysis
90 anemic patients
Group 1 received
using the student t-test
from New Delhi,
TXA 10mg/kg
(P>0.05)
India
Group 2 received
Less blood loss found
Johns Hopkins
15mg/kg
in the two study
Evidence Appraisal:
groups when
Control received
compared to the
Strength:l
control
Demographic data
(P<0.05)
Quality: Strong
were compared using
the Chi-square test. To There was no other
compare quantitative significant adverse
data between two
event such as deep
groups t-test was used vein thrombosis or
other thrombotic
events up to 24 h
post-operatively

Conclusion:
TXA 10mg/kg and
15mg/kg are found to
safely control
bleeding with no
proven adverse effects

Study was
randomized and
continued for two
years
Chi-square and t-test
were used to organize
data
Blood loss was
measured in
containers and weight
of saturated pads

Limitations:
Sample size of only
90 women
No specific adverse
effects were reviewed
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Author Recommendations: TXA Repeat study with larger sample size. TXA may effectively
reduce bleeding among at risk populations especially women in developing countries
Implications:
Midwives may consider TXA for at risk patients or anemic patients during the time of delivery
to minimize bleeding.
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Source:
Gungorduk, K., Ascoğlu, O., Yldrm, G., Ark, C., Tekirdağ, A. I., & Besmoglu, B. (2013).
Can intravenous injection of tranexamic acid be used in routine practice with
active management of the third stage of labor in vaginal delivery? A randomized
controlled study. Obstetrical & Gynecological Survey, 68(10), 673–675.
https://doi.org/10.1097/01.ogx.0000436756.05118.cd
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Purpose:
To determine
effectiveness of TXA
on third and fourth
stage of labor
Sample/Setting:
Department of
Obstetrics and
Gynecology,
Kanuni Sultan
Süleyman Teaching
Hospital, Istanbul,
Turkey

Strengths:
Experimental study
Participants were
randomized into two
groups through a
number system. TXA
group received 1g/
10ml diluted in 20ml
of 5% glucose while
placebo group
received 30ml
Glucose

Blood loss in third
and fourth stage of
labor lower in TXA
group (261.5 + or 146.8 versus 349.98 +
or - 188.85 mL,
respectively;
(p < 0.001)
Pph lower in txa
group (15, 6.8%; RR
= 3.76; 95% CI [1.27
to 11.15], p = 0.01).

Meds given 5 minutes
after anterior shoulder More women in the
control group needed
was extracted
uterotonics (RR =
3.18; 95% [CI 1.29 to
454 women who were
7.81], p = 0.007)
32 to 40 weeks
pregnant with high
Similar Hb in both
and low risk
groups (9.9 1.4 g/dL
pregnancies
and 9.3 0.9 g/dL,
Johns Hopkins
Evidence Appraisal:

respectively;
(p<0.001)
Conclusion:

Strength:l
Quality:Good
TXA can decrease
blood loss during 3rd
and 4th stages of
labor

Both low risk and
high risk vaginal
deliveries were
considered
Participants and
researchers were
double blinded to
preserve the integrity
of the experiment
(Gungorduk et al.,
2013)
Limitations:
Sample size was small
and may not reflect
the general public
Cost efficiency of
TXA was not included
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Author Recommendations:
TXA can be helpful for at risk patients during the 3rd and fourth stages of labor. TXA should
be given within 5 min of anterior shoulder delivery.
Implications:
Midwives can consider TXA for their at risk patients. Also TXA use may be useful for
midwives in underdeveloped countries where other uterotonics may be unavailable.
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Source:
Lakshmi, S. D. (2016). Role of prophylactic tranexamic acid in reducing blood loss during
elective caesarean section: A randomized controlled study. Journal of Clinical
And Diagnostic Research, 10(12), QC17–QC21. https://doi.org/10.7860/jcdr/
2016/21702.9050
Purpose/Sample

Design
(Method/
Instruments)

Results

Strengths/
Limitations
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Purpose:
To analyse the
effectiveness of
Tranexamic Acid
(TXA) in reducing
blood loss during
elective caesarean
section.

Sample/Setting:
120 women having
elective c-sections
within the PSG
Hospital.

Johns Hopkins
Evidence Appraisal:
Strength:l
Quality: good

Strengths:
The study is a
interventional,
randomized, parallel
group study
The study was done
from June 2014 to
May 2015

Women were
randomly placed in a
control or
independent group by
computer database.
Women in the TXA
group received 1g of
txa 20 min before
section. Control group
was given sodium
chloride. Both
Groups were given 10
units of oxytocin after
surgery.
T-test and chi squared
used to compare
variables
Hemoglobin was
assessed before and
after birth

There was less blood
loss from the time of
placental delivery to
the end of surgery
347.17ml blood loss
in the study group
versus 517.72ml in
control group (p <
0.001)

The study included
chi squares to verify
and compare variables
Hemoglobin levels
were checked before
and after birth to
show differences in
blood loss between
the TXA and placebo
group

Researchers observed
which groups would
have more than a 10% Computer data base
fall in hemoglobin
was used to
randomize women
9.3% of subjects in
which insured
study group and 39% randomization was
of subjects in control done correctly
group had more than
10% fall in
haemoglobin (p <
Limitations:
0.01)
Blood collected in
No danger was found drapes and sheets
to neonate
were not connected
blood loss was
Conclusion:
approximated
TXA can safely
control bleeding after
c-sections.

Long term effects of
TXA not considered
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Author Recommendations: Patients should receive TXA 20 minutes prior to surgery. Women
who receive TXA will have a decrease in blood loss postpartum.

Implications:
Midwives may advise the use of TXA for patients at risk for blood loss or anemic patients.
Providers should acknowledge the importance of administering TXA 20 minutes prior to
incision time for optimal effects.
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Source: Ononge, S., Mirembe, F., Wandabwa, J., & Campbell, O. M. (2016). Incidence and
risk
factors for postpartum hemorrhage in Uganda. Reproductive Health, 13(1), Article 38.
https://doi.org/10.1186/s12978-016-0154-8
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Design
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Purpose:
To assess risk factors
associated with
postpartum
hemorrhaging

Sample/Setting:
1188 women giving
birth in rural Uganda.

Johns Hopkins
Evidence Appraisal:
Strength:llI
Quality: Strong

Strengths:
Hemorrhaging risk
Prospective cohort
factors were greater
study done from 2013 among mothers who
to 2014 in six
had macrosomia
hospitals in rural
deliveries (aOR =
Uganda. Women
2.14, 95% CI [1.02,
given questionnaires 4.47], p= 0.01 ).
to assess their risk for
hemorrhaging
HIV positive also had
increased risk for
Participants had
postpartum bleeding
drapes placed under
sero-status (aOR =
them to confirm
2.26, 95% CI [1.20,
postpartum
4.25], p = 0.03)
hemorrhage
Hemorrhaging was
defined as bleeding
over 500ml in vaginal
deliveries and
1,000ml during a csection.

The researchers
created two multi
variable logistic
regression models for
the variables

Risk factors for
hemorrhaging was
acknowledged in both
vaginal and c-section
deliveries
The large population
size makes the
information
generalizable

Study was done for at
least a year
Limitations:

cesarean section
delivery were at
greatest risk for
postpartum
hemorrhaging ((aOR
= 7.54, 95% CI [4.11,
13.81], p <0.001)

Conclusion:
Maternal PPH is one
of the leading causes
of death among
mothers globally.

Study was limited to
rural Uganda.
Developed countries
were not included
which may impact the
risk factors for
women in that area
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Author Recommendations:
Recommends that further studies are done on PPH. The authors also recommend that more
studies are done on treatment options for postpartum hemorrhaging.
Implications:
Recommends that further studies are done on PPH. The authors also recommend that more
studies are done on treatment options for postpartum hemorrhaging.
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Source: Ramesh, A. C., Rajni, S., & Deka, N. (2015). Efficacy of tranexamic acid in
decreasing blood
loss during and after cesarean section: A randomized case controlled
prospective study. Indian Journal of Public Health Research & Development,
6(2), 12–16. https://doi.org/10.5958/0976-5506.2015.00063.7
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Purpose:
To study efficacy of
blood loss c-section

Randomized case
controlled study

This is an
Sample/Setting:
experimental study
200 women scheduled from July 2011 To
to have c-section
September 2013.
deliveries in the
department of
The study used
Obstetrics &
computer data to
Gynecology,
randomize women
Padmashree Dr. D.
into control and
Y. Patil Medical
independent groups.
College, Hospital and The TXA group
Research Center
received 1g of TXA
Pimpri
over minutes 20
minutes before the
incision while the
Johns Hopkins
control received
Evidence Appraisal: sodium chloride. Both
l
groups received
prophylactic oxytocin
Strength:l
post surgery.
Quality: Good

Difference in blood
loss from time of
delivery to placental
removal ( p Value
< 0.001 )

Significant difference
in blood loss from
inoperative time to
placental removal
( p < 0.001 )
No difference in
blood loss from time
of incision to
placental removal (p
= 0.056)
LSCS to two hours
post-partum with
mean blood loss of
3.80 ml in the study
group versus 112.25
ml in the control
group ( p < 0.001 ).
Study group had less
blood loss from
placental delivery to
two hours postpartum
(p = 0.002)
TXA had no effects
on newborn AGARs
(p = 0.5)
Conclusion:

TXA was found to
reduce blood loss
during postpartum

Strengths:
Study was done over
for a year
Vital signs were
monitored before and
after the c-section to
monitor effects of the
surgery
The studies findings
were compared to
other research on
TXA and postpartum
hemorrhaging.
Limitations:
The study should be
repeated with a larger
participant group

High risk women
were excluded from
the delivery
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Author Recommendations:
TXA should be avoided in individuals with a history of thrombosis. TXA can prevent blood
loss in low risk c-sections. Further studies are needed to determine the effect of TXA on high
risk women.
Implications:
If a midwife’s workplace allows her to be in the OR she should state if the patient has a history
of thrombosis. Although thrombosis is not likely, midwives should monitor for it and observe
newborn AGARS.
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Source:
Roberts, I., Shakur, T., Coats, T., Hunt, B., Balogun, E., Barneston, L., Cook, L.,
Kawahara, T., Perel, P., Prieto-Merino, D., Ramos, M., Cairns, J., & Guerriero, C.
(2013). The CRASH-2 trial: A randomised controlled trial and economic evaluation of
the effects of tranexamic acid on death, vascular occlusive events and transfusion
requirement in bleeding trauma patients. Health Technology Assessment, 18(3), 1–79.
https://doi.org/10.1108/cgij.2013.24818caa.005
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Purpose:

Strengths:
Experimental study

To assess early use of
TXA and its effects
on death
Sample/Setting:
Randomized
controlled
20, 211 adult trauma
patients were studied
from 274 hospitals
across 40 countries
Johns Hopkins
Evidence Appraisal:
l
Strength:l
Quality: Strong

All-cause mortality
was significantly
A computer randomly reduced with
assigned trauma
tranexamic acid ( M =
patients to TXA group 1463 [14·5%]
or placebo.TXA group tranexamic acid group
received 1g of the
vs ( M = 1613
drug over 10 minutes [16·0%] placebo
then again over 2 hr.
group; RR = 0·91,
Placebo group
95% CI [0·85–0·97],
received placebo the
p = 0·0035)
same way.
Risk of death lower in
placebo group 4.9%
vs 5.7% ; (relative risk
= 0·85, 95% CI
[0·76–0·96], p =
0·0077).
Conclusion:
TXA can effectively
reduce mortality rates
among trauma
patients who receive
TXA.

Large population size
from various
countries makes
information
generalizable
Patients were
randomized thorough
computer data which
kept the experiment
double blinded
Limitations:
Fibrinolytic agents in
TXA was not
measured
Do to injuries it was
difficult to measure
blood loss in trauma
patients
Early TXA was not
compared to late TXa

Author Recommendations:
Authors recommend TXA could be effective in the event of a postpartum hemorrhage. TXA
could be given to a wide range of trauma patients to reduce risk of death.
Implications: Although this article explored trauma patients a midwife may consider the use
of TXA for patients who have experienced vaginal trauma during a delivery. This cloud
includes shoulder dystocia, or a third or fourth degree vaginal laceration.
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Source: Roy, P., Sujatha, M. S., Bhandiwad, A., & Biswas, B. (2016). Role of tranexamic acid
in
reducing blood loss in vaginal delivery. The Journal of Obstetrics and
Gynecology of India, 66(S1), 246–250. https://doi.org/10.1007/s13224-016-0856-4
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Purpose:

Strengths:
mean fall in
TXA ability to reduce
haemoglobin was
blood loss in vaginal
This study started Oct 0.20 g % in study
Patients were
delivery
2014 to March 2025. group and 0.70 g % in randomized thorough
Sample/Setting:
control group
computer data which
The TXA group
kept the experiment
100 participants from
received IM oxytocin
double blinded
antenatal ward or
and TXA IV over 10 Mean fall in
labour ward of JSS
min while the control haematocrit was 0.40 There was a standard
Medical College and
group received IM
% in the study group for measuring blood
Hospital, Mysore
oxytocin and sodium and 1.20 % in the
loss among the two
Johns Hopkins
chloride over 10 min. control group.
groups
Evidence Appraisal: l Women in the study
could be no more
The mean blood loss Limitations:
Strength:l
than second gravita,
at the end of 2 hr was
38wk or above and
105 ml in the study
Fibrinolytic agents in
Quality: Good
having spontaneous
group and 252 ml in
TXA was not
labor.
the control group
measured
Randomized control

Pads and collector
drape were measured
two hours
postpartum.
Statistical analysis
was used to measure
mean, median and
standard deviation.

22 % of the patients
in the control group
needed additional
uterotonics compared
to only 2 % in the
study group, which
was statistically
significant
Conclusion:

The study only
consisted of 100
people
Not all p values were
discussed

Only healthy women
were included in the
TXA can effectively study so it is not
reduces bleeding and known how TXA
need for additional
could help high risk
uterotonics in normal deliveries
vaginal deliveries
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Author Recommendations:
The other recommends that TXA is used prophylactically to prevent hemorrhage even in
normal spontaneous labor.
Implications:
The midwife may consider TXA as prophylactic treatment during vaginal deliveries. TXA
should be given within 5 minutes of the delivery before a potential hemorrhage begins.
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Source:
Rushulo, K., Ranjit, s, & Rameswar, s. (2016). Effect of intravenous administration of
tranexamic acid in reducing blood loss during and after caesarean section. Journal of
Medical Science and Clinical Research, 4(7), 11297–11303. https://doi.org/10.18535/
jmscr/v4i7.19

Purpose/Sample

Design
(Method/
Instruments)

Purpose:
To determine
effectiveness of TXA
to prevent bleeding
during and after a csection

Randomized control
study from 2013 to
2015

Sample/Setting:
60 women with low
risk pregnancies from
India between the
ages of 24 to 40 years
old
Johns Hopkins
Evidence Appraisal:
Strength:l
Quality: Good

Experiment was
reviewed by the
institution of the
ethics committee

Results

Strengths/
Limitations
Strengths:

Blood loss from time
of surgery completion
to two hours was less
in sthe study group
48.7 ml and 58.4, (p =
0.001)

Study was conducted
for an extended period
of time
Assess effects of TXA
on various age groups
Limitations:

Patients with high risk
pregnancies, and
history of abdominal
surgery were
excluded

Blood loss from time
of incision to two
hours postpartum was Small sample size
significantly lower in
Did not observe HCT
the study group (p =
or PLT prior to the
0.001).
surgery

TXA 10mg/kg given
10 minutes prior to
incision

Conclusion:

Control group
received sodium
chloride 10 minutes
prior to incision

Excluded high risk
pregnancies

TXA can safely
reduce bleeding
among c-section
patients

Author Recommendations: Further research is needed to determine TXA effect of high risk
patients and to observe potential side effects associated with the drug.
Implications: Midwives may give TXA to prevent a postpartum hemorrhage among patients
with low risk pregnancies to prevent PPH.
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Source:
Sentilhes, L., Winer, N., Azria, E., Sénat, M., Ray, C. L., Vardon, D., Perrotin, F.,
Desbriére, R., Fuchs, F., Kayem, G., Ducarme, G., Doret-Dion, M., Huissoud, C.,
Bohec, C., Dureulle, P., Darsonval, A., Chrétien, J. -M., Seco, A., Daniel, V., &
Deneux-Tharaux, C. (2018). Tranexamic acid for the prevention of blood loss after
vaginal delivery.
New England Journal of Medicine, 379(8), 731–742. https://doi.org/10.1056/
nejmoa1800942
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Purpose:
To determine the
effectiveness of
prophylactic TXA
when given with
oxytocin during
vaginal deliveries

Strengths:
The experiment was
experimental double
blind study.

Postpartum
hemorrhage, defined
as blood loss of at
Sample/Setting:
least 500 ml blood
From Jan 2015 to Dec loss measured in
2016
collector bags

Women in the TXA
group had lower rates
of postpartum
hemorrhaging
7.8% vs. 10.4%
RR = 0.74, 95% CI
[0.61 to 0.91] p =
0.004; P = 0.04)

TXA group required
4,079 participants
less uterotonics
The study was done
Computer system was 7.2% vs. 9.7% of the
within 15 French
used to randomize
control group RR =
hospitals. Participants women into control
0.75, 95% CI [0.61 to
had to be at least 35
groups or independent 0.92], P = 0.006;
weeks gestation with groups. Women in the adjusted P = 0.04)
a singleton and
independent group
expecting a vaginal
received
thromboembolic
delivery. All
episodes between the
participants were 18
Experiment was
two groups did not
years old and up
divided into two parts differ by three months
group 1 received TXA postpartum 0.1% and
and oxytocin or TXA 0.2%, RR = 0.25;
Johns Hopkins
and placebo 2 min
95% CI [0.03 to 2.24].
Evidence Appraisal: after delivery . Group
2 received oxytocin
Strength:l
and TXA or oxytocin Conclusion:
and placebo 10 min
Quality: Strong
post delivery
Prophylactic TXA
could improve
Student t test
maternal outcomes
compared
after vaginal
deliveries
Chi-squared and
Fisher's test were used
to compare
categorical variables

Postpartum
hemorrhage was
measured by collector
bags
The study was done
for a year with a large
sample size including
women at risk for
hemorrhage
Expresses side effects
related to TXA such
as nausea and
vomiting
Limitations:
Prenatal hemoglobin
blood tests were done
at outside laboratories
which were not
completed at a
standard time.
Hemorrhaging was set
as bleeding over
500ml instead of
bleeding of 500ml
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Author Recommendations:
TXA should be considered for women at risk for hemorrhaging. For example, TXA could
decrease bleeding risk for women with episiotomy and operative vaginal deliveries.

Implications:
The midwife should consider TXA for her patients at risk for hemorrhaging. TXA should be
given at least 10 minutes post delivery.
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Source:
Senturk, M. B., Cakmak, Y., Yildiz, G., & Yildiz, P. (2012). Tranexamic acid for cesarean
section: A double-blind, placebo-controlled, randomized clinical trial. Archives of Gynecology
and Obstetrics, 287(4), 641–645. https://doi.org/10.1007/s00404-012-2624-8
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Purpose:
To assess the
effectiveness of TXA
among c-section
patient
Sample/Setting:
223 patients with
healthy pregnancies
across hospitals in
Berlin
Johns Hopkins
Evidence Appraisal:
Strength:l
Quality: Good

Strengths:
Greater loss of
hemoglobin in control The experiment
group than study
assessed HCT and
Experiment was
group (p = 0,034)
PLT before and after
approved by
the c-section
Higher HCT and PLT
TXA group was given loss in control group
1g of TXA 10
vs the study group (p
minutes prior to the
= 0.002, p = 0.003)
Limitations:
cesarean incision
while the control was
Study did not provide
given sodium chloride No increase risk
statistical evidence to
factor for stroke found prove limited risk
All patients were
in mother or baby up factors associated
given oxytocin after
to two weeks
with TXA
the surgery was
postpartum
completed
Oxytocin may have
Conclusion:
impacted the results
Hemoglobin
of the study
hematocrit and
platelet was assess
prior to the cesarean
TXA effectively
section
prevents PPH without
increasing risk for
Patients with increase stroke.
BMI, history of
venous
thromboembolism,
heart disease, active
liver or kidney
diseases, overweight
fetus, or allergies to
TXA did not
participate in this
study
Randomized double
blinded experiment

Author Recommendations:
Author recommends TXA may be beneficial among women having natural vaginal deliveries
and vaginal trauma. Recommends using TXA prior to birth or within minutes of birth for
optimal effect.
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Implications:
Midwives may consider TXA use among vaginal deliveries. TXA would be especially helpful
among women with cervical, vaginal and rectal lacerations.
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Source: Sofiene, B. M., Zied, H., Laidi, B. N., Yahya, M., & Hayen, M. (2015). A comparison
of two doses of tranexamic acid to reduce blood loss during cesarean delivery. Global
Anesthesia and Perioperative Medicine, 1(4), 93–95. https://doi.org/10.15761/gapm.1000123
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Purpose:
To determine the
efficiency of TXA on
c-section deliveries
after two doses
Sample/Setting:
52 participants
fromTunis maternity
and neonatology
center

Johns Hopkins
Evidence Appraisal:
Strength:l
Quality: Good

The study was
experimental.
52 women who
received regular
prenatal care and
consented for
Pfannenstiel csections. Participants
were randomized into
two groups 10 mg/kg
(group1) or 15 mg/kg
(group 2)of
tranexamic acid
intravenously. TXA
was given from 5 min
prior to c-sections.
Primary outcomes
were determined by
blood loss within 6
hours. Secondary
outcomes were
determined by the
total amount of
oxytocin given and
hemoglobin levels.
Statistical packages
for social sciences
were used to analyze
data.
Patients with PPH risk
factors were excluded
from the study.

Strengths:
Mean blood loss was
lower in TXA TXA2
group (p = 0.017)

Blood loss volume
was measured by
Gross’s formulas

Mean hematocrit
value was similar in
both groups (p =
0.081)

Student t tests were
used to compare the
two independent
groups

Less oxytocin was
needed in TXA group
2 (p = 0.05)

Limitations:

Conclusion:

TXA effectiveness in
aat risk patients were
not studied

Intravenous TXA 15
mg/kg was most
effective in
decreasing blood loss
and lowering the need
for additional
uterotonics.

The study was done
for a short period of
time.
Also, the sample size
was small meaning
the findings from the
study may not
represent the general
public

Author Recommendations: The author recommends that 15 mg/kg be used to control
postpartum bleeding instead of 10 mg/kg. The author also recommends that TXA is given 5
minutes prior to the initial c-section incision.
Implications:
TXA may be considered for healthy patients who have scheduled cesarean sections. Providers
should be cautious to administer TXA at least 5 minutes prior to the c-section.
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Source:
Woman Trial Collaborators. (2017). Effect of early tranexamic acid administration on
mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage
(WOMAN): An international, randomised, double-blind, placebo-controlled trial. Obstetrical
& Gynecological Survey, 72(9), 525–526. https://doi.org/10.1097/01.ogx.0000524474.98785.1
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Purpose:
To determine the
effects of early TXA
administration on
maternal death and
hysterectomy
outcomes.

Sample/Setting:
Women 16 years or
older. The study had
20,000 participants
from 193 hospitals in
211 countries.
Participants had to be
having a postpartum
hemorrhage to be a
part of the study.
Johns Hopkins
Evidence Appraisal:
Strength: l
Quality: Strong

Randomized double
blinded experiment
from March 2010 to
April 2016.

When given within 3
hours of birth risk of
death related to
hemorrhaging
decreased in patients
Postpartum
who received TXA
hemorrhage was
(RR = 0·81, 95% CI
categorized as more
[0·65–1·00], p =
than 500ml of loss
0·045). 1.2% of
after a vaginal
women died related to
delivery and 1000ml hemorrhaging in the
of blood loss after a c- TXA group while
section. The study
1.7% passed away in
was a double blind,
the placebo group
randomized, placebo (RR = 0·69, 95% CI
controlled trial study. [0·52–0·91] p =
0·008) .
Participants randomly
received 1g of TXA
There was little
or sodium chloride 1g difference in death
placebo. If
rates between the
participants continued TXA and placebo
to bleed after the first groups when TXA
dose or 24hr within
was given after 3
the first dose they
hours (RR = 1·07,
were given a second
95% CI [0·76–1·51],
dose of TXA 1g or
p = 0·70).
placebo 1g.
Participants were
given random
Risk of hysterectomy
numbers. These
was not reduced when
numbers were sent to given TXA compared
drug manufacturers
to the control
who then randomly
group( RR = 1·02,
sent TXA or sodium
95% CI [0·88–1·07] p
chloride with those
= 0·84).
matching numbers
Also, the use for
uterine tamponade,
manual placenta
removal and atrial
ligation were not
significantly different

Strengths:
The study randomized
women into TXA and
placebo groups using
group numbers. These
numbers were then
used to randomly
assign TXA or the
placebo to
participants. This kept
the study randomized
and double blinded.
The study had 20,000
women. The results
from this study can be
used for the general
public. The study
shared all their
findings which made
the study more
trustworthy.
The study was done
from March 2010 to
April 2016. The
researchers continued
the study for six years
to ensure they had
accurate results.
Limitations:

Some women died
related to blood loss
during the study. In
addition, ways to
prevent these deaths
were not explored.
TXA may be needed
for developed
countries and low
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Author Recommendations:
The study recommends that TXA treatment is done within 3 hours of birth. TXA after 3 hours
of delivery was not found to improve patient outcomes. Researchers also suggest that a study is
done on TXA given in ways other than intravenously to facilitate TXA use in developed
countries and home births .
Implications: Midwives could consider administering TXA to treat postpartum hemorrhaging
and improve patient outcomes. According to the study patients have the best outcomes when
TXA is given within 3 hours of birth time.

Source:Wong, J., Abrishami, A., El Beheiry, H., Mahomed, N. N., Roderick D., J., Gandhi, R.,
Syed, K. A., Ovais Hasan S. M., De Silva, Y., & Chung, F. (2010). Topical application of
tranexamic acid reduces postoperative blood loss in total knee arthroplasty. The Journal of
Bone and Joint Surgery, 92(15), 2503–2513. https://doi.org/10.2106/jbjs.i.01518
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Purpose:
To determine the
efficiency of topical
TXA.
Sample/Setting: 124
orthopedic patients
having total knee
arthroplasty from.
Johns Hopkins
Evidence Appraisal:
Strength: l
Quality: Good

Strengths:
Randomized control

Results showed a
significant reduction
in bleeding among the
TXA group by 20% to
25% (p < .017).

Group one received
1.5g of TXA while
group 2 was given 3g.
The control group was Also, significantly
given a placebo
increasing
hemoglobin levels by
Hemoglobin and
16% to 17% (p <
hematocrit were
.017) compared to the
assessed pre and post control group were
operation.
found.

Hemoglobin and
hematocrit were
assessed pre and post
operation.
Dopplers were used to
assess groups for
DVT.
Limitations:
The experiment had a
small study sample.

Dopplers were used to TXA was not found to
assess groups for
increase risk of DVT. No statistical data to
DVT
show TXA impact on
DVT pulmonary
Conclusion:
embolisms .
Topical TXA was
effective in reducing
blood loss.

Author Recommendations: Topical TXA should be applied immediately to the wound site to
minimize bleeding.
Implications: The findings from this study reflect the potential for topical TXA use in
obstetrical care. Topical TXA may be considered for severe vaginal lacerations and especially
cervical bleeds.

Source: Xu, J., Gao, W., & Ju, Y. (2012). Tranexamic acid for the prevention of postpartum
hemorrhage after cesarean section: A double-blind randomization trial. Archives of Gynecology
and Obstetrics, 287(3), 463–468. https://doi.org/10.1007/s00404-012-2593-y
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Purpose:
Determine TXA
ability to control
blood loss after a csection.

This is a double-blind The control and TXA
randomization trial
groups had similar
blood loss from
174 women receiving placental extraction to
primary pfannenstiel c-section closing.
c-sections were
336.7 ml and control
randomized. The
group 368.5 ml.
Sample/Setting:
intervention group
received 10mg/kg in a TXA group had lower
174 women in a
200ml syringe of
rates of blood loss
Grade IIIA hospital,
TXA prior to the
when bleeding was
Daqing Oilfield
placement of spinal
assessed two hours
General Hospital
incision while the
after c-section (p =
consented for primary control group
0.02), TXA group
c-sections and TXA
received 200ml of
(46.6 ml) compared to
treatment
sodium chloride.
the control group
(84.7 ml.
Participants were
Johns Hopkins
randomized using
Postpartum
Evidence Appraisal: numbered sealed
hemorrhage ended in
envelopes.
65 women in the
Strength: l
control group and 81
Postpartum bleeding of the TXA group (p =
Quality: good
was measured using
0.01).
suction containers,
soaked gauze, pads
Hemoglobin
and sanitary towels.
concentration was
similar in thoth
Bleeding was
groups
assessed from time of (p = 0.14) or platelet
placental extraction to count (p = 0.75)
c-section completion.
Then again from the
Conclusion:
end of the c-section to
two hours post birth.
TXA can decrease
The two groups were maternal blood loss
presented by twoand morbidity for csample Student’s t
section patients.
test. Data was then
compared using
Pearson Chi-square
test

Strengths:
The study was
reviewed by the
Committee on
Clinical Investigation
which ensured ethical
values were being
preserved.
Postpartum bleeding
was observed twice
which allowed
researchers to learn
how bleeding would
evolve after the csection.
Experiment was
double blinded to
preserve the integrity
of the study.
Student’s t test and
Pearson Chi-square
test to present and
compare data

Limitations:
Only 174 participants
were included which
means results may not
reflect the general
population.
Participants were
randomized using
numbered sealed
envelopes instead of
electronic data which
leaves room for error.
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Author Recommendations:
Author recommends that a larger study is done to determine potential adverse effects
associated with TXA use. C-section patients should be given 10mg/kg of TXA prior to the
operation to improve postpartum bleeding. TXA is not recommended for patients with
thrombosis, heart, brain and liver disease.
Implications: Although it is not in the midwife's scope of practice to perform c-sections the
midwife may recommend prophylactic TXA for her patient requiring primary c-sections. The
midwife should avoid TXA use in patients with a history of thrombosis, liver, heart and brain
disease.

